Buy Rating Affirmed on Trevi Therapeutics Amid Strong Clinical Trial Progress and Positive ...
Analyst Mayank Mamtani from B.Riley Financial maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report) and keeping the ...
The Pharma Letter1 天
Trevi updates on clinical progress for chronic cough treatment
Trevi Therapeutics has achieved key milestones in its clinical programs for Haduvio (nalbuphine), a treatment targeting ...
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of James V. Cassella, Ph ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ...
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc.: Trevi Therapeutics Provides Update on Haduvio's Clinical ...
Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) stud ...